Dolutégravir : un nouvel inhibiteur de l'intégrase dans l'arsenal thérapeutique anti-VIH

Integrase inhibitors are now key molecules in the composition of first line combined antiretroviral therapy due to their excellent potency and tolerability. Dolutegravir, a new integrase inhibitor, has been launched recently. It has some advantages over other integrase inhibitors, including a once-daily administration with no food requirements and no need for pharmacological boosting, with a low potential for drug-drug interactions, and a higher genetic barrier against HIV resistance. It has proven its efficacy in treatment-naive as well as treatment-experienced patients, with excellent clinical and biological tolerability. The recent launch of a single tablet regimen with a fixed dose combination of abacavir, lamivudine and dolutegravir makes dolutegravir an interesting option for the treatment of people living with HIV.